264 related articles for article (PubMed ID: 27217767)
21. Irreversible electroporation of the porcine kidney: Temperature development and distribution.
Wagstaff PG; de Bruin DM; van den Bos W; Ingels A; van Gemert MJ; Zondervan PJ; Verdaasdonk RM; van Lienden KP; van Leeuwen TG; de la Rosette JJ; Laguna Pes MP
Urol Oncol; 2015 Apr; 33(4):168.e1-7. PubMed ID: 25557146
[TBL] [Abstract][Full Text] [Related]
22. Irreversible electroporation: a new ablation modality--clinical implications.
Rubinsky B; Onik G; Mikus P
Technol Cancer Res Treat; 2007 Feb; 6(1):37-48. PubMed ID: 17241099
[TBL] [Abstract][Full Text] [Related]
23. Application of Irreversible Electroporation Ablation as Adjunctive Treatment for Margin Enhancement: Safety and Efficacy.
Simmerman E; Chung J; Lawson A; Kruse E
J Surg Res; 2020 Feb; 246():260-268. PubMed ID: 31610354
[TBL] [Abstract][Full Text] [Related]
24. Irreversible Electroporation (IRE) in Renal Tumors.
Narayanan G; Doshi MH
Curr Urol Rep; 2016 Feb; 17(2):15. PubMed ID: 26769468
[TBL] [Abstract][Full Text] [Related]
25. Irreversible Electroporation: A Novel Ultrasound-guided Modality for Non-thermal Tumor Ablation.
Hsiao CY; Huang KW
J Med Ultrasound; 2017; 25(4):195-200. PubMed ID: 30065492
[TBL] [Abstract][Full Text] [Related]
26. Irreversible Electroporation of the Pancreas.
Chan G; Pua U
Semin Intervent Radiol; 2019 Aug; 36(3):213-220. PubMed ID: 31435129
[TBL] [Abstract][Full Text] [Related]
27. [Research Progress of Catheter-based Irreversible Electroporation for Tissue Ablation].
Zhou Y; Han X; Ren F; Li Q; Chen X; Chu D; Wu R; Lyu Y
Zhongguo Yi Liao Qi Xie Za Zhi; 2020 Feb; 44(2):172-178. PubMed ID: 32400994
[TBL] [Abstract][Full Text] [Related]
28. Irreversible electroporation ablation: is all the damage nonthermal?
Faroja M; Ahmed M; Appelbaum L; Ben-David E; Moussa M; Sosna J; Nissenbaum I; Goldberg SN
Radiology; 2013 Feb; 266(2):462-70. PubMed ID: 23169795
[TBL] [Abstract][Full Text] [Related]
29. Irreversible electroporation for the ablation of liver tumors: are we there yet?
Charpentier KP
Arch Surg; 2012 Nov; 147(11):1053-61. PubMed ID: 23165618
[TBL] [Abstract][Full Text] [Related]
30. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
[TBL] [Abstract][Full Text] [Related]
31. Histological Response to 5 kHz Irreversible Electroporation in a Porcine Liver Model.
Kim HB; Baik KY; Sung CK
Technol Cancer Res Treat; 2023; 22():15330338231171767. PubMed ID: 37125478
[TBL] [Abstract][Full Text] [Related]
32. Irreversible electroporation (Nanoknife® treatment) in the field of hepatobiliary surgery: Current status and future perspectives.
Kourounis G; Paul Tabet P; Moris D; Papalambros A; Felekouras E; Georgiades F; Astras G; Petrou A
J BUON; 2017; 22(1):141-149. PubMed ID: 28365947
[TBL] [Abstract][Full Text] [Related]
33. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).
Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB
Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201
[TBL] [Abstract][Full Text] [Related]
34. Irreversible Electroporation for the Ablation of Renal Cell Carcinoma: A Prospective, Human, In Vivo Study Protocol (IDEAL Phase 2b).
Buijs M; van Lienden KP; Wagstaff PG; Scheltema MJ; de Bruin DM; Zondervan PJ; van Delden OM; van Leeuwen TG; de la Rosette JJ; Laguna MP
JMIR Res Protoc; 2017 Feb; 6(2):e21. PubMed ID: 28209559
[TBL] [Abstract][Full Text] [Related]
35. Mathematical modeling of the thermal effects of irreversible electroporation for
Agnass P; van Veldhuisen E; van Gemert MJC; van der Geld CWM; van Lienden KP; van Gulik TM; Meijerink MR; Besselink MG; Kok HP; Crezee J
Int J Hyperthermia; 2020; 37(1):486-505. PubMed ID: 32423258
[No Abstract] [Full Text] [Related]
36. Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by "electric field sinks".
Golberg A; Bruinsma BG; Uygun BE; Yarmush ML
Sci Rep; 2015 Feb; 5():8485. PubMed ID: 25684630
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Hepatic Lesions After non-Thermal Tumor Ablation by Irreversible Electroporation in a Pig Model.
Jeon SM; Davaa E; Jiang Y; Jenjob R; Truong NT; Shin KJ; Jeong S; Yang SG
Technol Cancer Res Treat; 2023; 22():15330338221147122. PubMed ID: 37861099
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements.
Campelo S; Valerio M; Ahmed HU; Hu Y; Arena SL; Neal RE; Emberton M; Arena CB
APL Bioeng; 2017 Dec; 1(1):016101. PubMed ID: 31069281
[TBL] [Abstract][Full Text] [Related]
39. Irreversible electroporation and electrochemotherapy in oncology: State of the art.
Tasu JP; Tougeron D; Rols MP
Diagn Interv Imaging; 2022 Nov; 103(11):499-509. PubMed ID: 36266192
[TBL] [Abstract][Full Text] [Related]
40. Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation (IRE).
Kos B; Voigt P; Miklavcic D; Moche M
Radiol Oncol; 2015 Sep; 49(3):234-41. PubMed ID: 26401128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
